A Phase 2 interventional study of Dupilumab in Nasal Polyps, Asthma, Aspirin-Induced and Aspirin-Exacerbated Respiratory Disease, sponsored by Brigham and Women's Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing dupilumab in Nasal Polyps — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Nasal Polyps.
Among the 16 studies testing dupilumab in Nasal Polyps, this one is the 13th largest by enrollment, is one of 3 that started in 2023, is one of 2 in phase 2, and was the 9th registered.
236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.
Browse Nasal Polyps studies →4 of the 16 studies testing dupilumab in Nasal Polyps are open now, in 2 countries. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
University of Virginia · Sites in United States
Ages 18–65
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
16 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2023.
This study's enrollment of 17 is below the median of 60 across 181 interventional studies indexed under Nasal Polyps.
Median enrollment 45 across the 16 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 16 have an industry lead sponsor. The 10 most frequent:
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Brigham and Women's Hospital has 5 studies filed under Nasal Polyps — fewer than ten, so there is no comparison to draw.
1 of the studies testing dupilumab in Nasal Polyps that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07268313Rigshospitalet, DenmarkComplete Remission After Treatment With Biologics for Nasal Polyps | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing dupilumab in Nasal Polyps, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).
The protocol involves an 8-week study of dupilumab in patients with CRSwNP and/or AERD. Participants will have 4 total doses of dupilumab administered, with each dose administered every 2 weeks. There will be full clinical assessments and biospecimen collections at Baseline (Visit 1), Week 2 (Visit 2), and Week 8 (Visit 3).
Key Inclusion Criteria:
History of AERD, defined as meeting the diagnostic triad with:
Key Exclusion Criteria:
Note: Other inclusion and exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive dupilumab (300mg every-other-week for 8 weeks).
Drug: Dupilumab
8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.
Also known as: Dupilumab Prefilled Syringe [Dupixent]
Nasal Fluid Levels of LTE4
The nasal fluid levels of LTE4 will be measured at week 8 and will serve as a surrogate biomarker of respiratory mast cell activation or burden.
Time frame: At Week 8 (Visit 3)
Nasal Fluid Levels of Albumin
The nasal fluid levels of albumin will be measured at week 8 and serve as a surrogate biomarker of nasal epithelial cell integrity.
Time frame: At Week 8 (Visit 3)
Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
Patients' sense of smell will be assessed at week 8 using the UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified)
Time frame: At Week 8 (Visit 3)
Rhinoscopic Total Polyp Score (TPS)
The extent of patients' nasal polyps will be assessed at week 8 using a TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst.
Time frame: At Week 8 (Visit 3)
Peak Nasal Inspiratory Flow (PNIF)
Patients' nasal congestion will be assessed at week 8 by a PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst.
Time frame: At Week 8 (Visit 3)
Quality of Life - 22-Item Sino-Nasal Outcome Test (SNOT-22)
Quality of life will be assessed at week 8 with a SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control).
Time frame: At Week 8 (Visit 3)
Lung Function - Forced Expiratory Volume 1 (FEV1)
Patients' lung function will be assessed at week 8 with an FEV1.
Time frame: At Week 8 (Visit 3)
Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
Asthma control will be measured at week 8 with an ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control.
Time frame: At Week 8 (Visit 3)
Number of Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) Leading to Study Drug Discontinuation
Safety will be measured by the number of treatment-related AEs and SAEs leading to dupilumab discontinuation.
Time frame: At Week 8 (Visit 3)
Change in Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified)
Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Rhinoscopic Total Polyp Score (TPS)
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst.
Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Peak Nasal Inspiratory Flow (PNIF)
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst.
Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in 22-Item Sino-Nasal Outcome Test (SNOT-22)
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control).
Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Lung Function - Forced Expiratory Volume 1 (FEV1)
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in FEV1.
Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control.
Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Nasal Fluid Levels of Eicosanoids
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid eicosanoid levels.
Time frame: weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Nasal Fluid Levels of Albumin
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid albumin levels.
Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Urinary Levels of Eicosanoids
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in urinary eicosanoid levels.
Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Serum Tryptase
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in serum tryptase levels.
Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in IgE Levels
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid and plasma levels of IgE.
Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Eosinophilic Cationic Protein (ECP)
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid levels of ECP.
Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
| Milestone | Dupilumab |
|---|---|
| Started | 17 |
| Completed | 17 |
| Not completed | 0 |
The nasal fluid levels of LTE4 will be measured at week 8 and will serve as a surrogate biomarker of respiratory mast cell activation or burden.
| ng per mg creatinine | Dupilumab |
|---|---|
| Nasal Fluid Levels of LTE4 | 0.01100 ± 0.01173 |
The nasal fluid levels of albumin will be measured at week 8 and serve as a surrogate biomarker of nasal epithelial cell integrity.
Results for this outcome have not been posted.
Patients' sense of smell will be assessed at week 8 using the UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified)
| Smell test score | Dupilumab |
|---|---|
| Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT) | 26.1 ± 10.6 |
The extent of patients' nasal polyps will be assessed at week 8 using a TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst.
| Score out of 8 | Dupilumab |
|---|---|
| Rhinoscopic Total Polyp Score (TPS) | 2.9 ± 2.5 |
Patients' nasal congestion will be assessed at week 8 by a PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst.
| Nasal flow in mL | Dupilumab |
|---|---|
| Peak Nasal Inspiratory Flow (PNIF) | 124.8 ± 46.2 |
Quality of life will be assessed at week 8 with a SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control).
| Score out of 110 | Dupilumab |
|---|---|
| Quality of Life - 22-Item Sino-Nasal Outcome Test (SNOT-22) | 17.6 ± 11.9 |
Patients' lung function will be assessed at week 8 with an FEV1.
| mL | Dupilumab |
|---|---|
| Lung Function - Forced Expiratory Volume 1 (FEV1) | 2.7 ± 0.7 |
Asthma control will be measured at week 8 with an ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control.
| Score out of 6 | Dupilumab |
|---|---|
| Asthma Control - Asthma Control Questionnaire-6 (ACQ-6) | 0.4 ± 0.4 |
Safety will be measured by the number of treatment-related AEs and SAEs leading to dupilumab discontinuation.
| Participants | Dupilumab |
|---|---|
| Number of Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) Leading to Study Drug Discontinuation | 0 |
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified)
Results for this outcome have not been posted.
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst.
Results for this outcome have not been posted.
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst.
Results for this outcome have not been posted.
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control).
Results for this outcome have not been posted.
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in FEV1.
Results for this outcome have not been posted.
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control.
Results for this outcome have not been posted.
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid eicosanoid levels.
Results for this outcome have not been posted.
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid albumin levels.
Results for this outcome have not been posted.
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in urinary eicosanoid levels.
Results for this outcome have not been posted.
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in serum tryptase levels.
Results for this outcome have not been posted.
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid and plasma levels of IgE.
Results for this outcome have not been posted.
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid levels of ECP.
Results for this outcome have not been posted.
Collected over From enrollment until end of study, up to 8 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dupilumab | 0/17 (0%) | 0/17 (0%) | 0/17 (0%) |
| Age, Continuous(Years) | Dupilumab |
|---|---|
| Mean | 51 ± 17 |
| Sex: Female, Male(Participants) | Dupilumab |
|---|---|
| Female | 10 |
| Male | 7 |
| Race (NIH/OMB)(Participants) | Dupilumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 16 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | Dupilumab |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 16 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2023 to primary completion in Apr 2026, 32 months.
Results were first posted in Nov 2026, 6 months after primary completion.
Of 24 phase 2 interventional studies under Nasal Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 32. This study's 32 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab
Brigham and Women's Hospital →